In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

Growing Pipelines, Promising Candidates Bring Gene Therapy To The Next Level

Advances in gene therapy have created a dynamic pipeline. A recent Datamonitor Healthcare report examines various trends in that pipeline, including vector types used, in vivo versus ex vivo approaches, and therapy areas being targeted.

Regenerative Medicine Market Intelligence
Advertisement

Latest From Market Intelligence

Transitions In The Trial Landscape: What Will Drive RCTs Into The Clinic?

Clinical trial execution is both a curse and a promise in the heated stakes for first-mover advantage in new drug development.  It’s a curse because siloed practices and legacy behaviors die hard – and it’s a promise because the volume of diverse data and a growing push for integration are finally closing the gap between research, evidence and the patient experience with disease.   New research from the Tufts University Center for the Study of Drug Development examines the struggle between these two forces and concludes that real change in the conduct of clinical trials is beginning to take root. 

Clinical Trials Research & Development

Deals In Depth: March 2018

Merck & Co and Eisai expanded upon a 2015 trial collaboration and signed a $5.8 billion alliance. Vertical integration in the health care services industry continued with Cigna's $67 billion acquisition of PBM Express Scripts. Siemens Healthineers' $5.2 billion IPO propelled device financing to $6bn.
Deals Market Intelligence

Deals Shaping The Medical Industry, May 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2018.

Deals Market Intelligence

Biopharma Quarterly Dealmaking Statistics, Q1 2018

Biopharma financing started the year solidly with $16.6 billion in total deal value, a 14% increase over the previous quarter. Q1 2018 biopharma merger and acquisition deal value, led by Cigna's $67 billion buy of Express Scripts, topped even the previous all-time-high set in Q4 2107, while alliances totaled $30.7 billion and featured big oncology and neurology partnerships.

BioPharmaceutical Deals

Billion Dollar Bets, Health Care Magic

Investments of over $100 million are now close to becoming the predominant class of venture capital deployed in the life sciences. What is behind this shift in venture investing and how might it impact companies' strategy to attract the big bucks.

Financing Market Intelligence

Deals Shaping The Medical Industry April 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2018. 

Deals BioPharmaceutical
See All
UsernamePublicRestriction

Register